News Focus
News Focus
Followers 37
Posts 3422
Boards Moderated 0
Alias Born 01/13/2017

Re: Grip it and Sip It post# 535271

Friday, 11/18/2022 7:25:34 PM

Friday, November 18, 2022 7:25:34 PM

Post# of 828291
If you compare NWBO to Kite and Juno you will see that $10-12/share is way too low.

They were CAR-T therapies (living cells like DCVAX) however there are major differences that make NWBO worth way more.

For example, those CAR-T therapies were generating single antigen T-cells instead of the full personalized repertoire.

2nd example, our phase 3 data set opens the door to a biomarker approval for MGMT methylated patients irrespective of tumor location. That market is way larger than attacking cd19 on acute lymphoblastic leukemia.

$40 is not impossible and that doesn't include any exuberance in trading and spikes that are seen in markets.

We need to get biotech sector moving, I've researched enough. Dendritic cell replacement is a staple that should've been offered years ago.

The entire market is pretty pathetic that's what makes the possibility for NWBO even stronger.. Everyone knows the whole market is trash right now.

Look and see for yourself...



A fake ass market is exactly how one can be a market maker and take both sides of every ticker, at all times, and somehow not go bankrupt. They sold you turds everywhere you look. Share prices bleed forever and then rise super quick and then they bleed again forever.
Bullish
Bullish


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News